Explore ›
Finding
Finding
improvement
Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and ART initiation prior to pregnancy.
| Effect size | aOR=0.34 |
| CI | 95% CI=0.12, 0.97 |
| Comparator | efavirenz-based ART (EFV + tenofovir/emtricitabine) during pregnancy |
| Effect summary | improvement; aOR=0.34; CI: 95% CI=0.12, 0.97 |
| Effect modifiers | [{"modifier": "ART initiation prior to pregnancy", "interaction_p": "p=0.57", "direction": "null", "stratum_details": "Fewer women conceived on DTG-based ART (31.5% vs 87.3%, p<0.01). Interaction term for ART at conception on DTG vs EFV relationship was not significant.", "plain_language": "Whether a woman started ART before or during pregnancy did not change the finding that DTG was associated with lower GDM risk compared to EFV.", "annotation_notes": ""}, {"modifier": "cumulative ART duration during pregnancy at OGTT", "interaction_p": "", "direction": "null", "stratum_details": "Duration of ART at OGTT: aOR=0.97 (95% CI=0.93, 1.02) per week. DTG group had shorter ART duration (16.7 vs 27.6 weeks). Adjusting for this did not change the DTG vs EFV finding (aOR=0.40, 95% CI=0.18, 0.92).", "plain_language": "How long a woman had been on ART during pregnancy did not explain the difference in GDM rates between DTG and EFV.", "annotation_notes": "Sensitivity analysis result. The shorter ART duration in the DTG group did not confound the DTG-EFV comparison."}] |
Connected entities
Interventions
Conditions
Outcomes
Populations
Source
PMC8373729
Gestational diabetes in women living with HIV in Botswana: Lower rates with dolutegravir- than efavirenz-based antiretroviral therapy